At the American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS) 2021 Fall Scientific Symposium, Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica, will receive an award for his work on floppy eyelid syndrome and using collagen cross-linking to stiffen the eyelid and help patients.
Richard Wasserman, MD, PhD, an allergist and immunologist with Allergy Partners of North Texas, an early adopter of food allergy oral immunotherapy (OIT), discusses how attitudes have changed around the practice.
To avoid bankrupting health care, providers must carefully consider how they use biologics in patients with severe asthma, according to a presenter at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, explains what he is most looking forward to at the 2021 conference of the American Academy of Ophthalmology (AAO).
David Ramsey, MD, PhD, MPH, previews a session at the American Academy of Ophthalmology 2021 conference that explores whether telehealth visits among patients with diabetes affected rates of completed in-person eye examinations.
While low- and middle-income countries remain desperate for a COVID-19 vaccine, the United States has entered a dangerous new phase of the pandemic, where antivaccine forces are exporting their antiscience beliefs to other countries, according to a keynote speaker at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
The American Academy of Ophthalmology conference is scheduled to take place in-person and online from November 12-15, 2021.
Carina Venter, PhD, RD, allergy specialist dietitian and associate professor in pediatric allergy and immunology at Children's Hospital Colorado and the University of Colorado, discusses the gut microbiome’s complex relationship with our immune system and diet diversity’s potential role in allergic disease and food allergy–related outcomes.
An afternoon session at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting focused on key updates in pediatric anaphylaxis from the past year as seen in published data.
Misinformation is not supported by the data on the science of vaccination, agreed experts during “Combating Misinformation in Science,” which took place at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Brian T. Kelly, MD, MA, FACAAI, Midwest Allergy and Asthma Clinic, and the American College of Allergy, Asthma & Immunology annual meeting program chair, discusses the importance of distinguishing between non–immunoglobulin E (IgE)– and IgE-mediated food allergies, as well as remaining up to date on guidance for eosinophilic esophagitis (EoE).
Peter Hotez, MD, PhD, FASTMH, professor of pediatrics and molecular virology and dean, National School of Tropical Medicine, Baylor College of Medicine, and codirector, Texas Children’s Hospital Center for Vaccine Development, addresses antivaccination sentiment and how to overcome it to find an optimal solution to end the COVID-19 pandemic.
With new and expected future options for treating atopic dermatitis (AD), including an injectable biologic and an oral small molecule inhibitor, which is preferred and which makes the most sense for patients?
In 2017, guidelines about when to feed peanuts to infants changed to recommend early feeding by 4 to 6 months of age depending on 3 risk levels, but these allergy prevention strategies are still not widespread, according to Ruchi Gupta, MD, MPH, professor of pediatrics and medicine, Northwestern Feinberg School of Medicine, who discussed the topic at the 2021 ACAAI Annual Scientific Meeting.
Two experts explore disparities in atopic dermatitis by age, skin color, and ethnicity.
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses how small molecule inhibitors are used in atopic dermatitis, as well as why there is no one-size-fits approach to implementing them in practice.
David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses the connection between health literacy and lack of trust in science and also addresses allergy concerns toward COVID-19 vaccines.
The 2021 ACAAI Annual Scientific Meeting, taking place virtually and in person in New Orleans, kicks off on Thursday, November 4, by focusing on dermatology and atopic dermatitis and concludes on Monday, November 8, with a final plenary session that addresses updates to several treatment guidelines.
Brian T. Kelly, MD, MA, FACAAI, Midwest Allergy and Asthma Clinic, and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting program chair, discusses how this year’s conference content will demonstrate the joint themes of innovation and diversity, as well as what exciting developments presenters and attendees alike should watch for.
Erika Glenn, Division Head of Sales, Care Management, CVS Health, addressed some of the latest innovations in predictive modeling and data analytics being leveraged by her organization in the management of patients with chronic conditions at the Asembia 2021 Specialty Pharmacy Summit in Las Vegas.
A panel at Asembia 2021 Specialty Pharmacy Summit in Las Vegas addressed challenges in the treatment journey of patients with rare diseases, efforts to improve access to gene therapies, and cost and value considerations for stakeholders.
Oncology drugs are a huge driver of cost, but there’s a lot of innovation happening in the space to improve care and outcomes for patients, said Michelle Booth, PharmD, director of specialty clinical solutions at Magellan Rx Management.
Panelists from a session at Asembia 2021 Specialty Pharmacy Summit in Las Vegas discussed considerations for manufacturers, specialty pharmacies, and payers entering the rare disease and gene therapy market.
The state of value-based contracting in specialty pharmacy was addressed in a panel discussion at Asembia 2021 Specialty Pharmacy Summit in Las Vegas, with speakers touching on the essentials of such agreements, how to optimally integrate them, and future considerations for the pharmaceutical marketplace.
Some policy reforms can help incentivize more use of value-based contracts, but overall an area that needs more work is value-based contracts with pharmaceutical companies, said Steven Peskin, MD, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
After the public health emergency is over, there will likely remain incentive to keep some administration of specialty therapies at home, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
Panelists of the opening session at Asembia 2021 Specialty Pharmacy Summit in Las Vegas address emerging shifts in specialty pharmacy, its impact on the health care system, and future implications post pandemic.
At the fully in-person meeting of the Asembia 2021 Specialty Pharmacy Summit, held in Las Vegas, Nevada, attendees will get multiple sessions looking into the future of specialty pharmacy, as well as sessions on hot topics like telehealth and health equity.
Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
In 2 sessions at the Asembia 2021 Specialty Pharmacy Summit, George Van Antwerp, MBA, managing director, Deloitte Consulting, will provide a look at the future of specialty pharmacy and health equity in pharmacy.
